vs
AXCELIS TECHNOLOGIES INC（ACLS）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
AXCELIS TECHNOLOGIES INC的季度营收约是再鼎医药的1.9倍（$238.3M vs $127.1M），再鼎医药同比增速更快（17.1% vs -5.6%），AXCELIS TECHNOLOGIES INC自由现金流更多（$-8.9M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs -2.8%）
Axcelis Technologies是一家美国半导体设备供应商，1995年成立，总部位于美国马萨诸塞州贝弗利。公司面向全球半导体制造行业，从事半导体生产核心设备的设计、制造及服务，主营产品包括高中电流、高能离子注入系统以及半导体芯片制造用固化系统。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
ACLS vs ZLAB — 直观对比
营收规模更大
ACLS
是对方的1.9倍
$127.1M
营收增速更快
ZLAB
高出22.7%
-5.6%
自由现金流更多
ACLS
多$17.8M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
-2.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $238.3M | $127.1M |
| 净利润 | $34.3M | — |
| 毛利率 | 47.0% | 51.0% |
| 营业利润率 | 15.2% | -54.6% |
| 净利率 | 14.4% | — |
| 营收同比 | -5.6% | 17.1% |
| 净利润同比 | -31.3% | — |
| 每股收益（稀释后） | $1.11 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACLSZLAB
| Q4 25 | $238.3M | $127.1M | ||
| Q3 25 | $213.6M | $115.4M | ||
| Q2 25 | $194.5M | $109.1M | ||
| Q1 25 | $192.6M | $105.7M | ||
| Q4 24 | $252.4M | $108.5M | ||
| Q3 24 | $256.6M | $101.8M | ||
| Q2 24 | $256.5M | $100.1M | ||
| Q1 24 | $252.4M | $87.1M |
净利润ACLSZLAB
| Q4 25 | $34.3M | — | ||
| Q3 25 | $26.0M | $-36.0M | ||
| Q2 25 | $31.4M | $-40.7M | ||
| Q1 25 | $28.6M | $-48.4M | ||
| Q4 24 | $50.0M | — | ||
| Q3 24 | $48.6M | $-41.7M | ||
| Q2 24 | $50.9M | $-80.3M | ||
| Q1 24 | $51.6M | $-53.5M |
毛利率ACLSZLAB
| Q4 25 | 47.0% | 51.0% | ||
| Q3 25 | 41.6% | 59.5% | ||
| Q2 25 | 44.9% | 60.6% | ||
| Q1 25 | 46.1% | 63.6% | ||
| Q4 24 | 46.0% | 61.5% | ||
| Q3 24 | 42.9% | 64.1% | ||
| Q2 24 | 43.8% | 64.9% | ||
| Q1 24 | 46.0% | 61.4% |
营业利润率ACLSZLAB
| Q4 25 | 15.2% | -54.6% | ||
| Q3 25 | 11.7% | -42.3% | ||
| Q2 25 | 14.9% | -50.3% | ||
| Q1 25 | 15.1% | -53.3% | ||
| Q4 24 | 21.6% | -62.6% | ||
| Q3 24 | 18.3% | -66.6% | ||
| Q2 24 | 20.6% | -76.0% | ||
| Q1 24 | 22.4% | -80.7% |
净利率ACLSZLAB
| Q4 25 | 14.4% | — | ||
| Q3 25 | 12.2% | -31.2% | ||
| Q2 25 | 16.1% | -37.3% | ||
| Q1 25 | 14.8% | -45.8% | ||
| Q4 24 | 19.8% | — | ||
| Q3 24 | 18.9% | -40.9% | ||
| Q2 24 | 19.8% | -80.2% | ||
| Q1 24 | 20.4% | -61.4% |
每股收益（稀释后）ACLSZLAB
| Q4 25 | $1.11 | $-0.05 | ||
| Q3 25 | $0.83 | $-0.03 | ||
| Q2 25 | $0.98 | $-0.04 | ||
| Q1 25 | $0.88 | $-0.04 | ||
| Q4 24 | $1.54 | $-0.09 | ||
| Q3 24 | $1.49 | $-0.04 | ||
| Q2 24 | $1.55 | $-0.08 | ||
| Q1 24 | $1.57 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $374.3M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.0B | $715.5M |
| 总资产 | $1.4B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ACLSZLAB
| Q4 25 | $374.3M | $689.6M | ||
| Q3 25 | $449.6M | $717.2M | ||
| Q2 25 | $549.8M | $732.2M | ||
| Q1 25 | $587.1M | $757.3M | ||
| Q4 24 | $571.3M | $779.7M | ||
| Q3 24 | $579.4M | $616.1M | ||
| Q2 24 | $548.3M | $630.0M | ||
| Q1 24 | $530.2M | $650.8M |
股东权益ACLSZLAB
| Q4 25 | $1.0B | $715.5M | ||
| Q3 25 | $1.0B | $759.9M | ||
| Q2 25 | $1.0B | $791.7M | ||
| Q1 25 | $1.0B | $810.8M | ||
| Q4 24 | $1.0B | $840.9M | ||
| Q3 24 | $975.6M | $667.7M | ||
| Q2 24 | $934.9M | $704.2M | ||
| Q1 24 | $901.7M | $762.2M |
总资产ACLSZLAB
| Q4 25 | $1.4B | $1.2B | ||
| Q3 25 | $1.4B | $1.2B | ||
| Q2 25 | $1.3B | $1.2B | ||
| Q1 25 | $1.3B | $1.2B | ||
| Q4 24 | $1.3B | $1.2B | ||
| Q3 24 | $1.3B | $985.3M | ||
| Q2 24 | $1.3B | $987.4M | ||
| Q1 24 | $1.3B | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-6.6M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $-8.9M | $-26.7M |
| 自由现金流率自由现金流/营收 | -3.7% | -21.0% |
| 资本支出强度资本支出/营收 | 1.0% | 0.5% |
| 现金转化率经营现金流/净利润 | -0.19× | — |
| 过去12个月自由现金流最近4个季度 | $107.0M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流ACLSZLAB
| Q4 25 | $-6.6M | $-26.0M | ||
| Q3 25 | $45.4M | $-32.0M | ||
| Q2 25 | $39.7M | $-31.0M | ||
| Q1 25 | $39.8M | $-61.7M | ||
| Q4 24 | $12.8M | $-55.8M | ||
| Q3 24 | $45.7M | $-26.8M | ||
| Q2 24 | $40.1M | $-42.2M | ||
| Q1 24 | $42.2M | $-90.1M |
自由现金流ACLSZLAB
| Q4 25 | $-8.9M | $-26.7M | ||
| Q3 25 | $43.3M | $-35.0M | ||
| Q2 25 | $37.7M | $-33.9M | ||
| Q1 25 | $34.8M | $-63.2M | ||
| Q4 24 | $8.1M | $-58.4M | ||
| Q3 24 | $41.8M | $-28.2M | ||
| Q2 24 | $38.1M | $-42.9M | ||
| Q1 24 | $40.6M | $-91.1M |
自由现金流率ACLSZLAB
| Q4 25 | -3.7% | -21.0% | ||
| Q3 25 | 20.3% | -30.4% | ||
| Q2 25 | 19.4% | -31.1% | ||
| Q1 25 | 18.1% | -59.9% | ||
| Q4 24 | 3.2% | -53.8% | ||
| Q3 24 | 16.3% | -27.7% | ||
| Q2 24 | 14.8% | -42.9% | ||
| Q1 24 | 16.1% | -104.5% |
资本支出强度ACLSZLAB
| Q4 25 | 1.0% | 0.5% | ||
| Q3 25 | 0.9% | 2.6% | ||
| Q2 25 | 1.0% | 2.6% | ||
| Q1 25 | 2.6% | 1.5% | ||
| Q4 24 | 1.8% | 2.4% | ||
| Q3 24 | 1.5% | 1.3% | ||
| Q2 24 | 0.8% | 0.7% | ||
| Q1 24 | 0.6% | 1.1% |
现金转化率ACLSZLAB
| Q4 25 | -0.19× | — | ||
| Q3 25 | 1.75× | — | ||
| Q2 25 | 1.27× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.26× | — | ||
| Q3 24 | 0.94× | — | ||
| Q2 24 | 0.79× | — | ||
| Q1 24 | 0.82× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACLS
| Products | $224.6M | 94% |
| Services | $13.7M | 6% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
